pipette
ESEspañol

Evaluation of vaccine-induced anti-lipopolysaccharide antibodies against clinically relevant Klebsiella pneumoniae strains to inform vaccine design

Robert M. Lawrence, Nathalie Karaky, Emma Bownes, Edward Hildebrand, Cristina Alaimo, Domenico Maione, Francesca Micoli, Kathryn E. Holt, Kelly L. Wyres, David Goldblatt

Peer-reviewed journalReal-world use

In the authors' words

Abstract Klebsiella pneumoniae is a leading cause of neonatal sepsis in low- and middle-income countries and is increasingly multi-drug resistant, highlighting the need for vaccines. Putative vaccine targets include the lipopolysaccharide (O antigen) and capsular polysaccharide (K antigen), but capsule may mask O antigen and limit antibody-mediated opsonophagocytosis. We evaluated the activity of O antigen-specific antibodies induced by a tetravalent bioconjugate vaccine against 146 clinical isolates representing 17 prevalent capsule types associated with neonatal sepsis. Susceptibility to antibody-mediated killing varied by capsule type: four were consistently susceptible, six showed heterogeneous responses, and seven were resistant despite remaining susceptible to K antigen-specific antibodies. Killing of susceptible strains was predominantly mediated by anti-O1 antibodies, as demonstrated by competitive inhibition with purified polysaccharides. Collectively, these findings support an antigen-sparing vaccine design strategy, in which susceptible capsule types may be replaced by a single O type, reducing vaccine complexity while maintaining broad functional coverage.

Main resultThe abstract does not state a limitation.

Appeared: Thursday, October 29. Nature Communications. Peer-reviewed journal.

DOI: 10.1038/s41467-026-79159-4